Zowall H - Search Results

1

Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor.

Grover SA, Coupal L, Zowall H, Weiss TW, Alexander CM. Grover SA, et al. Among authors: zowall h. Am J Med. 2003 Aug 1;115(2):122-8. doi: 10.1016/s0002-9343(03)00303-6. Am J Med. 2003. PMID: 12893398

2

The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. Grover SA, et al. Among authors: zowall h. Arch Intern Med. 2003 Feb 10;163(3):333-9. doi: 10.1001/archinte.163.3.333. Arch Intern Med. 2003. PMID: 12578514

3

Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?

Grover SA, Coupal L, Zowall H. Grover SA, et al. Among authors: zowall h. Hypertension. 2005 Jan;45(1):92-7. doi: 10.1161/01.HYP.0000149684.01903.b8. Epub 2004 Nov 15. Hypertension. 2005. PMID: 15545508

4

Cost-effectiveness of lipid-lowering treatment according to lipid level.

Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA. Pilote L, et al. Among authors: zowall h. Can J Cardiol. 2005 Jun;21(8):681-7. Can J Cardiol. 2005. PMID: 16003451

5

Costs of dyslipidemia.

Zowall H, Grover SA. Zowall H, et al. Expert Rev Pharmacoecon Outcomes Res. 2003 Jun;3(3):273-81. doi: 10.1586/14737167.3.3.273. Expert Rev Pharmacoecon Outcomes Res. 2003. PMID: 19807375

6

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. Hamilton VH, et al. Among authors: zowall h. JAMA. 1995 Apr 5;273(13):1032-8. JAMA. 1995. PMID: 7897787

7

Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Grover SA, et al. Among authors: zowall h. Arch Intern Med. 1998 Mar 23;158(6):655-62. doi: 10.1001/archinte.158.6.655. Arch Intern Med. 1998. PMID: 9521231

8

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Grover SA, Coupal L, Paquet S, Zowall H. Grover SA, et al. Among authors: zowall h. Arch Intern Med. 1999 Mar 22;159(6):593-600. doi: 10.1001/archinte.159.6.593. Arch Intern Med. 1999. PMID: 10090116

9

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.

Lowensteyn I, Coupal L, Zowall H, Grover SA. Lowensteyn I, et al. Among authors: zowall h. J Cardiopulm Rehabil. 2000 May-Jun;20(3):147-55. doi: 10.1097/00008483-200005000-00002. J Cardiopulm Rehabil. 2000. PMID: 10860196

10

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?

Grover SA, Coupal L, Zowall H, Dorais M. Grover SA, et al. Among authors: zowall h. Circulation. 2000 Aug 15;102(7):722-7. doi: 10.1161/01.cir.102.7.722. Circulation. 2000. PMID: 10942738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters